206258-44-8

Basic information

• Product Name: ethyl 4-[benzyl-(4-methoxybenzene-sulfonyl)-amino]-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate
• Synonyms: ethyl 4-[benzyl-(4-methoxybenzene-sulfonyl)-amino]-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate
• CAS NO: 206258-44-8
• Molecular Weight: 494.571
• Mol File: 206258-44-8.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: ethyl 4-[benzyl-(4-methoxybenzene-sulfonyl)-amino]-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 4-[benzyl-(4-methoxybenzene-sulfonyl)-amino]-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate(206258-44-8)
• EPA Substance Registry System: ethyl 4-[benzyl-(4-methoxybenzene-sulfonyl)-amino]-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate(206258-44-8)

Safety Data

• Hazardous Substances Data: 206258-44-8(Hazardous Substances Data)

Upstream product

• 20481-15-6 ethyl 4-chloro-1,3-dimethylpyrazolo[3,4-b]pyridine-5-carboxylate 
• 119059-70-0 N-benzyl-4-methoxybenzenesulfonamide 

Relevant articles and documents

Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors

Compounds of the formula which are useful in disease conditions mediated by TNF-α, such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.

Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors

This invention provides, low molecular weight, non-peptide inhibitors of matrix metalloproteinases and TNF-α converting enzyme (TACE, tumor necrosis factor-α converting enzyme) of formula: B wherein B is T, U, W, and X are each, independently, carbon or nitrogen, provided that when T or U is carbon, either may be optionally substituted with R1; Y is carbon, nitrogen, oxygen or sulfur, provided that at least one of T, U, W, X, and Y is not carbon, and further provided that no more than 2 of T, U, W, and X are nitrogen; is a phenyl ring or is a heteroaryl ring of ring 5-6 atoms which may contain 0-2 heteratoms selected from nitrogen, oxygen, and sulfur, in addition to any heteroatoms defined by W or X; wherein the phenyl or heteroaryl ring may be optionally mono-, di-, or tri- substituted with R1; Z is a phenyl, naphthyl, heteroaryl, or heteroaryl fused to phenyl, wherein the heteroaryl moiety contains of 5-6 ring atoms and 1-3 heteroatoms selected from nitrogen, oxygen, or sulfur; wherein the phenyl, naphthyl, heteroaryl, or phenyl fused heteroaryl moieties may be optionally mono-, di-, or tri- substituted with R1; R1 is hydrogen, halogen, alkyl of 1-8 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, cyclocalkyl of 3-6 carbon atoms, —(CH2)nZ, —OR2, —CN, —COR2, perfluoroalkyl of 1-4 carbon atoms, —CONR2R3, —S(O)xR2 —OPO(OR2)OR3, —PO(OR2)R3, —OC(O)NR2R3, —COOR2, —CONR2R3, —SO3H, —NR2R3, —NR2COR3, —NR2COOR3, —SO2NR2R3, —NO2, —N(R2)SO2R3, —NR2CONR2R3, —NR2C(═NR 3)NR2R3, —SO2NHCOR4, —CONHSO2R4, -tetrazol-5-yl, —SO2NHCN, —SO2NHCONR2R3 or Z; V is a saturated or partially unsaturated heterocycloalkyl ring of 5-7 ring atoms having 1-3 heteroatoms selected from N, O, or S, which may be optionally mono-, or di-substituted with R2; R2 and R3 are each, independently, hydrogen, alkyl of 1-8 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, cycloalkyl of 3-6 carbon atoms; perfluoroalkyl of 1-4 carbon atoms, Z or V; R4 is alkyl of 1-8 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, cycloalkyl of 3-6 carbon atoms; perfluoroalkyl of 1-4 carbon atoms, Z or V; R5 is hydrogen, alkyl of 1-8 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, Z, or V; n=1-6; x=0-2 or a pharmaceutically acceptable salt thereof.